Business Wire

Suzano Eucafluff to Attend INDEX and CIDPEX in 2023

3.2.2023 16:58:00 EET | Business Wire | Press release

Share

Suzano, the world’s largest hardwood pulp producer, will showcase its highly sustainable and innovative eucalyptus-based fluff pulp, Eucafluff®, at this year’s INDEX and CIDEPX conferences in Geneva and Nanjing, for the second consecutive year. These two conferences gather the pulp industry’s leading participants in nonwoven materials comprising decision-makers, managers, and technical personnel. Suzano will be presenting significant advancements in Eucafluff’s product application and performance.

INDEX is one of the world’s largest nonwovens exhibitions exploring the industry’s latest trends and innovations. The event takes place on 18-21 April 2023 in Geneva, Switzerland.

CIDPEX – The China International Disposable Paper Expo - is another important event for Suzano which stages the latest advancements across the tissue paper and disposable hygiene products sector. The event takes place on 12-16 May 2023 in Nanjing, China.

Eucafluff® is made from sustainably managed eucalyptus farms in São Paulo and is the result of nearly 15 years of R&D. Its absorbent panels, made with 100% Eucafluff®, provides a more flexible, more discreet product for consumers. Eucafluff® outperforms its competitors in terms of rewetting, net retention and comfort performance due to the morphology of Suzano’s eucalyptus hardwood, which is smaller, thinner, and highly compressible. The result of this performance provides significant affordability with an 18% reduction of packaging material and 13% reduction in storage and volume. Furthermore, Eucafluff® provides a far more sustainable solution with a smaller carbon footprint and a lower impact on land use, using far less wood to produce the same amount of fluff.

Eucafluff has grown dramatically in recent years, increasing its application and sales across a range of fluff segments. Suzano’s Eucafluff® will continue to pursue an ambitious growth strategy, particularly as it accelerates an ongoing roll-out to the baby diaper segment while also targeting the rapidly expanding adult diaper market.

About Suzano

Suzano is the world’s largest producer of hardwood pulp and the global leader in the innovation and production of renewable, bio-based materials for consumer and industrial use. Our responsibly-grown materials provide over 2 billion people in more than 100 countries with plastic free products including writing paper, tissue, paper cups and straws, paperboard packaging, toilet paper, textiles, diapers and more. We are pioneers in sustainable mass scale industrial production, and our ethos of innovability – the pursuit of sustainable solutions through innovation – is at the core of all our work, from the field to our factories and labs, all the way to the end user. Suzano’s history spans 100 years and is listed on the B3 stock exchange in Brazil (SUZB3) and the NYSE (SUZ) in the United States.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Hawthorn Advisors
Jamie Plotnek
suzano@hawthornadvisors.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther

TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release

TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt

Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye